- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06103864
Et fase III-studie af Dato-DXd med eller uden Durvalumab sammenlignet med investigators valg af kemoterapi i kombination med Pembrolizumab hos patienter med PD-L1 positiv lokalt recidiverende inoperabel eller metastatisk trippel-negativ brystkræft
Et fase III, åbent, randomiseret studie af Datopotamab Deruxtecan (Dato-DXd) med eller uden Durvalumab sammenlignet med Investigators valg af kemoterapi (Paclitaxel, Nab-paclitaxel eller Gemcitabin + Carboplatin) i kombination med Pembrolizumab-L1 Positiv PD Lokalt tilbagevendende inoperabel eller metastatisk trippel-negativ brystkræft (TROPION-Breast05)
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
The primary objective of the study is to demonstrate superiority of Dato-DXd + durvalumab relative to ICC + pembrolizumab by assessment of PFS as assessed by BICR in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
The study will be stratified based on geographic location (US/Canada/Europe vs. Dato-DXd monotherapy enrolling countries vs. rest of world), disease-free interval (DFI) history (de novo vs. prior DFI 6 to 12 months vs. prior DFI > 12 months), and prior PD-1/PD-L1 treatment for early stage TNBC (yes vs. no).
This study aims to see if Dato-DXd with durvalumab allows patients to live longer without their breast cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy and pembrolizumab. This study is also looking to see how the treatment and the breast cancer affects patients' quality of life.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Undersøgelse Kontakt Backup
- Navn: AstraZeneca Breast Cancer Study Locator Service
- Telefonnummer: +1-877-400-4656
- E-mail: az-bcsl@careboxhealth.com
Studiesteder
-
-
-
CABA, Argentina, 1425
- Rekruttering
- Research Site
-
CABA, Argentina, 1414
- Rekruttering
- Research Site
-
CABA, Argentina, C1425
- Trukket tilbage
- Research Site
-
CABA, Argentina, C1113AAE
- Rekruttering
- Research Site
-
Ciudad Autónoma Buenos Aires, Argentina, C1430EFA
- Rekruttering
- Research Site
-
Ciudad de Buenos Aires, Argentina, C1015ABO
- Rekruttering
- Research Site
-
Rosario, Argentina, 2000
- Rekruttering
- Research Site
-
San Nicolás de los Arroyos, Argentina, B2900
- Trukket tilbage
- Research Site
-
-
-
-
-
Camperdown, Australien, 2050
- Rekruttering
- Research Site
-
Darlinghurst, Australien, 2010
- Afsluttet
- Research Site
-
Heidelberg, Australien, 3084
- Afsluttet
- Research Site
-
Melbourne, Australien, 3000
- Rekruttering
- Research Site
-
Nedlands, Australien, 6009
- Rekruttering
- Research Site
-
Waratah, Australien, 2298
- Trukket tilbage
- Research Site
-
-
-
-
-
Barretos, Brasilien, 14784-400
- Rekruttering
- Research Site
-
Curitiba, Brasilien, 80730-150
- Rekruttering
- Research Site
-
Florianópolis, Brasilien, 88034-000
- Rekruttering
- Research Site
-
Goiânia, Brasilien, 74000-000
- Rekruttering
- Research Site
-
Itajaí, Brasilien, 88301-220
- Rekruttering
- Research Site
-
Porto Alegre, Brasilien, 90035-003
- Rekruttering
- Research Site
-
Recife, Brasilien, 52010-075
- Rekruttering
- Research Site
-
São Paulo, Brasilien, 01246-000
- Rekruttering
- Research Site
-
São Paulo, Brasilien, 01317-001
- Rekruttering
- Research Site
-
Teresina, Brasilien, 64049-200
- Rekruttering
- Research Site
-
-
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Rekruttering
- Research Site
-
Hamilton, Ontario, Canada, L8V 5C2
- Rekruttering
- Research Site
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- Research Site
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Rekruttering
- Research Site
-
Montreal, Quebec, Canada, H4A 3J1
- Rekruttering
- Research Site
-
Montreal, Quebec, Canada, H2X 0A9
- Rekruttering
- Research Site
-
Québec, Quebec, Canada, G1S 4L8
- Rekruttering
- Research Site
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Rekruttering
- Research Site
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Rekruttering
- Research Site
-
-
-
-
-
Cardiff, Det Forenede Kongerige, CF14 2TL
- Rekruttering
- Research Site
-
Chelsea, Det Forenede Kongerige, SW3 6JJ
- Rekruttering
- Research Site
-
Leicester, Det Forenede Kongerige, Le5 4PW
- Rekruttering
- Research Site
-
Liverpool, Det Forenede Kongerige, L7 8YA
- Afsluttet
- Research Site
-
London, Det Forenede Kongerige, EC1A 7BE
- Rekruttering
- Research Site
-
London, Det Forenede Kongerige, SW17 0QT
- Trukket tilbage
- Research Site
-
Oxford, Det Forenede Kongerige, OX3 7LE
- Suspenderet
- Research Site
-
Surrey, Det Forenede Kongerige, GU2 7XX
- Suspenderet
- Research Site
-
Sutton, Det Forenede Kongerige, SM2 5PT
- Rekruttering
- Research Site
-
Taunton, Det Forenede Kongerige, TA1 5DA
- Rekruttering
- Research Site
-
-
-
-
-
Bacolod, Filippinerne, 6100
- Rekruttering
- Research Site
-
Cebu City, Filippinerne, 6000
- Rekruttering
- Research Site
-
City of Muntinlupa, Filippinerne, 1780
- Rekruttering
- Research Site
-
Manila, Filippinerne, 1000
- Rekruttering
- Research Site
-
Quezon City, Filippinerne, 1112
- Rekruttering
- Research Site
-
San Juan City, Filippinerne, 1502
- Rekruttering
- Research Site
-
-
-
-
Alabama
-
Daphne, Alabama, Forenede Stater, 36526
- Rekruttering
- Research Site
-
-
Arkansas
-
Springdale, Arkansas, Forenede Stater, 72762
- Rekruttering
- Research Site
-
-
California
-
Duarte, California, Forenede Stater, 91010
- Trukket tilbage
- Research Site
-
Fountain Valley, California, Forenede Stater, 92708
- Ikke rekrutterer endnu
- Research Site
-
Glendale, California, Forenede Stater, 91204
- Rekruttering
- Research Site
-
Sacramento, California, Forenede Stater, 95817
- Rekruttering
- Research Site
-
Santa Rosa, California, Forenede Stater, 95403
- Trukket tilbage
- Research Site
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80012
- Rekruttering
- Research Site
-
Denver, Colorado, Forenede Stater, 80210
- Ikke rekrutterer endnu
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06510
- Rekruttering
- Research Site
-
-
Florida
-
Altamonte Springs, Florida, Forenede Stater, 32701
- Ikke rekrutterer endnu
- Research Site
-
Jacksonville, Florida, Forenede Stater, 32256
- Trukket tilbage
- Research Site
-
Miami, Florida, Forenede Stater, 33176
- Rekruttering
- Research Site
-
Palm Bay, Florida, Forenede Stater, 32909
- Trukket tilbage
- Research Site
-
Plantation, Florida, Forenede Stater, 33324
- Rekruttering
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30318
- Suspenderet
- Research Site
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96819
- Trukket tilbage
- Research Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- Research Site
-
Decatur, Illinois, Forenede Stater, 62526
- Trukket tilbage
- Research Site
-
Elmhurst, Illinois, Forenede Stater, 60126
- Trukket tilbage
- Research Site
-
Naperville, Illinois, Forenede Stater, 60540
- Trukket tilbage
- Research Site
-
-
Indiana
-
New Albany, Indiana, Forenede Stater, 47150
- Trukket tilbage
- Research Site
-
-
Iowa
-
Des Moines, Iowa, Forenede Stater, 50309
- Rekruttering
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40503
- Trukket tilbage
- Research Site
-
Louisville, Kentucky, Forenede Stater, 40202
- Trukket tilbage
- Research Site
-
Louisville, Kentucky, Forenede Stater, 40207
- Trukket tilbage
- Research Site
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70809
- Rekruttering
- Research Site
-
Baton Rouge, Louisiana, Forenede Stater, 70808
- Trukket tilbage
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21215
- Trukket tilbage
- Research Site
-
Columbia, Maryland, Forenede Stater, 21044
- Rekruttering
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02111
- Trukket tilbage
- Research Site
-
Worcester, Massachusetts, Forenede Stater, 01655
- Trukket tilbage
- Research Site
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48201
- Rekruttering
- Research Site
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Trukket tilbage
- Research Site
-
-
Minnesota
-
Saint Paul, Minnesota, Forenede Stater, 55109
- Rekruttering
- Research Site
-
-
Mississippi
-
Hattiesburg, Mississippi, Forenede Stater, 39401
- Trukket tilbage
- Research Site
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63129
- Rekruttering
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87109
- Rekruttering
- Research Site
-
-
New York
-
Albany, New York, Forenede Stater, 12206
- Trukket tilbage
- Research Site
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Research Site
-
Stony Brook, New York, Forenede Stater, 11794-7263
- Rekruttering
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45219
- Rekruttering
- Research Site
-
Cincinnati, Ohio, Forenede Stater, 45245
- Rekruttering
- Research Site
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Research Site
-
-
Pennsylvania
-
York, Pennsylvania, Forenede Stater, 17403
- Trukket tilbage
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02903
- Rekruttering
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, Forenede Stater, 37404
- Rekruttering
- Research Site
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Research Site
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75246
- Rekruttering
- Research Site
-
Dallas, Texas, Forenede Stater, 75230
- Trukket tilbage
- Research Site
-
Dallas, Texas, Forenede Stater, 75246
- Trukket tilbage
- Research Site
-
El Paso, Texas, Forenede Stater, 79902
- Rekruttering
- Research Site
-
Flower Mound, Texas, Forenede Stater, 75028
- Trukket tilbage
- Research Site
-
Fort Worth, Texas, Forenede Stater, 76104
- Trukket tilbage
- Research Site
-
Houston, Texas, Forenede Stater, 77054
- Trukket tilbage
- Research Site
-
Houston, Texas, Forenede Stater, 77090
- Trukket tilbage
- Research Site
-
Houston, Texas, Forenede Stater, 77098
- Trukket tilbage
- Research Site
-
Kingwood, Texas, Forenede Stater, 77339
- Trukket tilbage
- Research Site
-
McKinney, Texas, Forenede Stater, 75071
- Trukket tilbage
- Research Site
-
Sugar Land, Texas, Forenede Stater, 77479
- Rekruttering
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22903
- Rekruttering
- Research Site
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Research Site
-
Midlothian, Virginia, Forenede Stater, 23114
- Rekruttering
- Research Site
-
Norfolk, Virginia, Forenede Stater, 23502
- Rekruttering
- Research Site
-
Roanoke, Virginia, Forenede Stater, 24014
- Rekruttering
- Research Site
-
-
Washington
-
Tacoma, Washington, Forenede Stater, 98405
- Rekruttering
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- Trukket tilbage
- Research Site
-
-
-
-
-
Lille, Frankrig, 59000
- Rekruttering
- Research Site
-
Lyon, Frankrig, 69373
- Rekruttering
- Research Site
-
Montpellier, Frankrig, 34298
- Rekruttering
- Research Site
-
Paris, Frankrig, 75020
- Rekruttering
- Research Site
-
Saint-Herblain, Frankrig, 44805
- Rekruttering
- Research Site
-
Toulouse, Frankrig, 31059
- Rekruttering
- Research Site
-
Vandœuvre-lès-Nancy, Frankrig, 54511
- Rekruttering
- Research Site
-
Villejuif, Frankrig, 94800
- Rekruttering
- Research Site
-
-
-
-
-
Hong Kong, Hong Kong, 999077
- Rekruttering
- Research Site
-
-
-
-
-
Calicut, Indien, 673601
- Trukket tilbage
- Research Site
-
Chennai, Indien, 600031
- Rekruttering
- Research Site
-
Jaipur, Indien, 302004
- Trukket tilbage
- Research Site
-
Kochi, Indien, 682027
- Trukket tilbage
- Research Site
-
Kolkata, Indien, 700160
- Trukket tilbage
- Research Site
-
Kottayam, Indien, 686008
- Rekruttering
- Research Site
-
Marg Jaipur, Indien, 302004
- Rekruttering
- Research Site
-
Mohali, Indien, 160055
- Rekruttering
- Research Site
-
Mysuru, Indien, 570017
- Rekruttering
- Research Site
-
Nagpur, Indien, 440001
- Rekruttering
- Research Site
-
Nashik, Indien, 422009
- Rekruttering
- Research Site
-
New Delhi, Indien, 11029
- Rekruttering
- Research Site
-
New Delhi, Indien, 110075
- Rekruttering
- Research Site
-
Puducherry, Indien, 605006
- Rekruttering
- Research Site
-
Surat, Indien, 395002
- Rekruttering
- Research Site
-
Thiruvananthapuram, Indien, 695011
- Rekruttering
- Research Site
-
Vadodara, Indien, 391760
- Rekruttering
- Research Site
-
Visakhapatnam, Indien, 530053
- Trukket tilbage
- Research Site
-
-
-
-
-
Bergamo, Italien, 24127
- Rekruttering
- Research Site
-
Empoli, Italien, 50053
- Rekruttering
- Research Site
-
Milan, Italien, 20132
- Rekruttering
- Research Site
-
Milan, Italien, 20141
- Rekruttering
- Research Site
-
Modena, Italien, 41124
- Trukket tilbage
- Research Site
-
Naples, Italien, 80131
- Rekruttering
- Research Site
-
Padova, Italien, 35128
- Rekruttering
- Research Site
-
Reggio Emilia, Italien, 42123
- Rekruttering
- Research Site
-
Roma, Italien, 00168
- Rekruttering
- Research Site
-
Rozzano, Italien, 20089
- Rekruttering
- Research Site
-
-
-
-
-
Akashi-shi, Japan, 673-8558
- Rekruttering
- Research Site
-
Bunkyō City, Japan, 113-8431
- Rekruttering
- Research Site
-
Bunkyō City, Japan, 113-8677
- Rekruttering
- Research Site
-
Chiba, Japan, 260-8717
- Rekruttering
- Research Site
-
Chūōku, Japan, 104-0045
- Rekruttering
- Research Site
-
Fukuoka, Japan, 811-1395
- Rekruttering
- Research Site
-
Fukushima, Japan, 960-1295
- Rekruttering
- Research Site
-
Gifu, Japan, 501-1194
- Rekruttering
- Research Site
-
Hidaka-shi, Japan, 350-1298
- Rekruttering
- Research Site
-
Hiroshima, Japan, 734-8551
- Rekruttering
- Research Site
-
Hiroshima, Japan, 730-8518
- Rekruttering
- Research Site
-
Isehara-shi, Japan, 259-1193
- Rekruttering
- Research Site
-
Kamogawa-shi, Japan, 296-8602
- Rekruttering
- Research Site
-
Kashiwa, Japan, 277-8577
- Rekruttering
- Research Site
-
Kitaadachi-gun, Japan, 362-0806
- Rekruttering
- Research Site
-
Kumamoto, Japan, 860-8556
- Rekruttering
- Research Site
-
Kurume-shi, Japan, 830-0011
- Rekruttering
- Research Site
-
Kōtoku, Japan, 135-8550
- Rekruttering
- Research Site
-
Matsuyama, Japan, 791-0280
- Rekruttering
- Research Site
-
Nagoya, Japan, 466-8560
- Rekruttering
- Research Site
-
Nagoya, Japan, 467-8602
- Rekruttering
- Research Site
-
Niigata, Japan, 951-8566
- Rekruttering
- Research Site
-
Nishinomiya-shi, Japan, 663-8501
- Rekruttering
- Research Site
-
Okayama, Japan, 700-8558
- Rekruttering
- Research Site
-
Osaka, Japan, 541-8567
- Rekruttering
- Research Site
-
Osakasayama-shi, Japan, 589-8511
- Rekruttering
- Research Site
-
Ota-shi, Japan, 373-8550
- Rekruttering
- Research Site
-
Sapporo, Japan, 003-0804
- Rekruttering
- Research Site
-
Sendai, Japan, 980-8574
- Rekruttering
- Research Site
-
Shinagawa-ku, Japan, 142-8666
- Rekruttering
- Research Site
-
Shinjuku-ku, Japan, 162-8655
- Rekruttering
- Research Site
-
Shinjuku-ku, Japan, 160-0023
- Rekruttering
- Research Site
-
Tsu, Japan, 514-8507
- Rekruttering
- Research Site
-
Tsukuba, Japan, 305-8577
- Rekruttering
- Research Site
-
Yokohama, Japan, 241-8515
- Rekruttering
- Research Site
-
-
-
-
-
Anyang, Kina, 455000
- Rekruttering
- Research Site
-
Beijing, Kina, 100044
- Rekruttering
- Research Site
-
Beijing, Kina, 100142
- Rekruttering
- Research Site
-
Bengbu, Kina, 233004
- Rekruttering
- Research Site
-
Changchun, Kina, 130021
- Rekruttering
- Research Site
-
Changsha, Kina, 410008
- Rekruttering
- Research Site
-
Changsha, Kina, 410013
- Rekruttering
- Research Site
-
Chengdu, Kina, 610000
- Rekruttering
- Research Site
-
Chengdu, Kina, 610041
- Rekruttering
- Research Site
-
Chongqing, Kina, 400030
- Trukket tilbage
- Research Site
-
Fuzhou, Kina, 350014
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510120
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510060
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510700
- Rekruttering
- Research Site
-
Hangzhou, Kina, 310009
- Rekruttering
- Research Site
-
Hangzhou, Kina, 310022
- Rekruttering
- Research Site
-
Hangzhou, Kina, 310016
- Rekruttering
- Research Site
-
Harbin, Kina, 150081
- Rekruttering
- Research Site
-
Hefei, Kina, 230031
- Rekruttering
- Research Site
-
Jinan, Kina, 250021
- Aktiv, ikke rekrutterende
- Research Site
-
Meizhou, Kina, 514031
- Rekruttering
- Research Site
-
Nanchang, Kina, 330009
- Rekruttering
- Research Site
-
Nanjing, Kina, 210009
- Rekruttering
- Research Site
-
Nanjing, Kina, 2100008
- Rekruttering
- Research Site
-
Nanning, Kina, 530021
- Rekruttering
- Research Site
-
Shandong, Kina
- Rekruttering
- Research Site
-
Shanghai, Kina, 200025
- Rekruttering
- Research Site
-
Shanghai, Kina, 200080
- Afsluttet
- Research Site
-
Shenyang, Kina, 110004
- Rekruttering
- Research Site
-
Taiyuan, Kina, 030000
- Rekruttering
- Research Site
-
Tianjin, Kina, 300000
- Rekruttering
- Research Site
-
Wenzhou, Kina, 325000
- Rekruttering
- Research Site
-
Wuhan, Kina, 430022
- Rekruttering
- Research Site
-
Wuhan, Kina, 430079
- Rekruttering
- Research Site
-
Xi'an, Kina, 710061
- Rekruttering
- Research Site
-
Xiamen, Kina, 361003
- Rekruttering
- Research Site
-
Xintai, Kina, 54031
- Rekruttering
- Research Site
-
Xuzhou, Kina, 221009
- Rekruttering
- Research Site
-
Zhanjiang, Kina, 524003
- Rekruttering
- Research Site
-
Zhengzhou, Kina, 450008
- Rekruttering
- Research Site
-
Zhengzhou, Kina, 450052
- Rekruttering
- Research Site
-
-
-
-
-
CD Mexico, Mexico, 04980
- Rekruttering
- Research Site
-
Guadalajara, Mexico, 44670
- Trukket tilbage
- Research Site
-
Guadalajara, Mexico, 44638
- Rekruttering
- Research Site
-
Mexico City, Mexico, 0 3100
- Rekruttering
- Research Site
-
Mexico City, Mexico, 06760
- Rekruttering
- Research Site
-
México, Mexico, 04700
- Rekruttering
- Research Site
-
Tuxtla Gutiérrez, Mexico, 29090
- Rekruttering
- Research Site
-
-
-
-
-
Bialystok, Polen, 15-027
- Trukket tilbage
- Research Site
-
Bydgoszcz, Polen, 85-796
- Trukket tilbage
- Research Site
-
Gdansk, Polen, 80-952
- Rekruttering
- Research Site
-
Gdynia, Polen, 81-519
- Trukket tilbage
- Research Site
-
Konin, Polen, 62-500
- Trukket tilbage
- Research Site
-
Krakow, Polen, 31-501
- Rekruttering
- Research Site
-
Krakow, Polen, 31-115
- Trukket tilbage
- Research Site
-
Legnica, Polen, 59-220
- Trukket tilbage
- Research Site
-
Lodz, Polen, 90-302
- Rekruttering
- Research Site
-
Lublin, Polen, 20-090
- Trukket tilbage
- Research Site
-
Przemyśl, Polen, 37-700
- Trukket tilbage
- Research Site
-
Warsaw, Polen, 02-781
- Rekruttering
- Research Site
-
Wroclaw, Polen, 53-413
- Trukket tilbage
- Research Site
-
-
-
-
-
Singapore, Singapore, 169610
- Rekruttering
- Research Site
-
Singapore, Singapore, 308433
- Rekruttering
- Research Site
-
Singapore, Singapore, 217562
- Rekruttering
- Research Site
-
Singapore, Singapore, 119228
- Trukket tilbage
- Research Site
-
-
-
-
-
Barcelona, Spanien, 8035
- Rekruttering
- Research Site
-
Barcelona, Spanien, 08028
- Trukket tilbage
- Research Site
-
Granada, Spanien, 18016
- Rekruttering
- Research Site
-
Hospitalet deLlobregat, Spanien, 08907
- Rekruttering
- Research Site
-
Madrid, Spanien, 28007
- Rekruttering
- Research Site
-
Madrid, Spanien, 28034
- Trukket tilbage
- Research Site
-
Pamplona, Spanien, 31008
- Rekruttering
- Research Site
-
Santander, Spanien, 39008
- Rekruttering
- Research Site
-
-
-
-
-
Cape Town, Sydafrika, 7570
- Rekruttering
- Research Site
-
Johannesburg, Sydafrika, 2013
- Rekruttering
- Research Site
-
Johannesburg, Sydafrika, 2196
- Rekruttering
- Research Site
-
Johannesburg, Sydafrika, 2193
- Rekruttering
- Research Site
-
Paarl, Sydafrika, 7646
- Rekruttering
- Research Site
-
Pretoria, Sydafrika, 0081
- Rekruttering
- Research Site
-
Pretoria, Sydafrika, 0081
- Afsluttet
- Research Site
-
-
-
-
-
Busan, Sydkorea, 49241
- Afsluttet
- Research Site
-
Daegu, Sydkorea, 41404
- Rekruttering
- Research Site
-
Goyang-si, Sydkorea, 10408
- Rekruttering
- Research Site
-
Seongnam-si, Sydkorea, 13620
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 03080
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 06351
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 05505
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 03722
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 06591
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 02841
- Rekruttering
- Research Site
-
Seoul, Sydkorea, 06273
- Rekruttering
- Research Site
-
-
-
-
-
Hsinchu, Taiwan, 300
- Rekruttering
- Research Site
-
Kaohsiung City, Taiwan, 80756
- Rekruttering
- Research Site
-
Taichung, Taiwan, 40447
- Rekruttering
- Research Site
-
Tainan, Taiwan, 704
- Rekruttering
- Research Site
-
Taipei, Taiwan, 100
- Rekruttering
- Research Site
-
Taipei, Taiwan, 112
- Rekruttering
- Research Site
-
Taipei, Taiwan, 10449
- Rekruttering
- Research Site
-
Taipei, Taiwan, 11259
- Rekruttering
- Research Site
-
Taoyuan, Taiwan, 333
- Rekruttering
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10210
- Rekruttering
- Research Site
-
Bangkok, Thailand, 10400
- Rekruttering
- Research Site
-
Bangkok, Thailand, 10330
- Rekruttering
- Research Site
-
Bangkok, Thailand, 10700
- Rekruttering
- Research Site
-
Chiang Mai, Thailand, 50200
- Rekruttering
- Research Site
-
Dusit, Thailand, 10300
- Rekruttering
- Research Site
-
Khon Kaen, Thailand, 40002
- Rekruttering
- Research Site
-
Songkhla, Thailand, 90110
- Rekruttering
- Research Site
-
-
-
-
-
Ankara, Tyrkiet (Türkiye), 6200
- Rekruttering
- Research Site
-
Ankara, Tyrkiet (Türkiye), 06520
- Rekruttering
- Research Site
-
Besevler Ankara, Tyrkiet (Türkiye)
- Rekruttering
- Research Site
-
Istanbul, Tyrkiet (Türkiye), 34010
- Rekruttering
- Research Site
-
Izmir, Tyrkiet (Türkiye), 35575
- Trukket tilbage
- Research Site
-
Küçükçekmece, Tyrkiet (Türkiye), 34295
- Rekruttering
- Research Site
-
Samsun, Tyrkiet (Türkiye), 55200
- Rekruttering
- Research Site
-
-
-
-
-
Düsseldorf, Tyskland, 40479
- Trukket tilbage
- Research Site
-
Essen, Tyskland, 45136
- Trukket tilbage
- Research Site
-
Georgsmarienhütte, Tyskland, 49124
- Trukket tilbage
- Research Site
-
Hamburg, Tyskland, 20357
- Trukket tilbage
- Research Site
-
Hanover, Tyskland, 30625
- Trukket tilbage
- Research Site
-
Heidelberg, Tyskland, 69120
- Trukket tilbage
- Research Site
-
Heilbronn, Tyskland, 74078
- Trukket tilbage
- Research Site
-
Leipzig, Tyskland, 04103
- Trukket tilbage
- Research Site
-
-
-
-
-
Da Nang, Vietnam, 550000
- Rekruttering
- Research Site
-
Hanoi, Vietnam, 100000
- Rekruttering
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Rekruttering
- Research Site
-
Huế, Vietnam, 530000
- Rekruttering
- Research Site
-
Hồ Chí Minh, Vietnam, 700000
- Rekruttering
- Research Site
-
Viet Tri, Vietnam, 35000
- Rekruttering
- Research Site
-
Vinh, Vietnam, 460000
- Rekruttering
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria
-
Histologically or cytologically documented locally recurrent inoperable, which cannot be treated with curative intent, or metastatic TNBC, as defined by the ASCO-CAP guidelines.
-
ECOG PS 0 or 1.
-
Participants are expected to provide an FFPE tumour sample collected from a locally recurrent inoperable or metastatic tumour. Alternatively, an archival FFPE tumour sample can be submitted; it must have been collected ≤ 3 years prior to the participant signing informed consent (screening start).
-
PD-L1 positive TNBC based on results from an appropriately validated investigational PD-L1 (22C3) assay (CPS ≥ 10) from a sponsor designated central laboratory.
-
No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.
- Patients with recurrent disease will be eligible if they have completed treatment for Stage I-III breast cancer, if indicated, and ≥6 months have elapsed between completion of treatment with curative intent and the first documented recurrence.
-
Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin).
-
Measurable disease as per RECIST 1.1.
-
Adequate bone marrow reserve and organ function.
-
Male and female participants of childbearing potential must agree to use protocol-specified method(s) of contraception.
Key Exclusion Criteria
-
As judged by investigator, any evidence of diseases (such as severe or uncontrolled medical conditions including systemic diseases, uncontrolled hypertension, serious gastrointestinal conditions associated with diarrhoea, chronic diverticulitis or previous complicated diverticulitis, history of allogeneic organ transplant, and active bleeding diseases, ongoing and active infection, significant cardiac conditions, substance abuse, psychiatric illness/social situation or psychological conditions) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
-
History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 2 years before Cycle 1 Day 1 and of low potential risk for recurrence.
-
Participants with a history of previously treated neoplastic spinal cord compression or treated, clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.
- Participants with treated clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.
-
Uncontrolled infection requiring IV antibiotics, antivirals or antifungals.
-
Active or uncontrolled hepatitis B or C virus infection.
-
Known HIV infection that is not well controlled.
-
Uncontrolled or significant cardiac disease.
-
History of non-infectious ILD/pneumonitis (including radiation pneumonitis) that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
-
Clinically severe pulmonary function compromise.
-
Clinically significant corneal disease.
-
Active or prior documented autoimmune or inflammatory disorders.
-
Prior exposure to any treatment including ADC containing a chemotherapeutic agent targeting topoisomerase I and TROP2-targeted therapy.
-
Any concurrent anti-cancer treatment.
-
Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors or Dato-DXd.
-
Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Dato-DXd + durvalumab
Arm 1: Dato-DXd + durvalumab |
Provided in 100mg vials. IV infusion. Experimental drug.
Andre navne:
Provided in 500mg vials. IV infusion. Experimental drug.
Andre navne:
|
|
Aktiv komparator: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab
Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) |
IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. |
|
Eksperimentel: Dato-DXd
Arm 3: Dato-DXd |
Provided in 100mg vials. IV infusion. Experimental drug.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression Free Survival (PFS)
Tidsramme: From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The comparison will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anticancer therapy or clinically progresses prior to RECIST 1.1 progression. However, if the participant progresses or dies immediately after 2 or more consecutive missed visits, the participant will be censored at the time of the latest evaluable assessment prior to the 2 missed visits. The measure of interest is the HR of PFS. |
From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival (OS)
Tidsramme: From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
|
OS is defined as the time from randomisation until the date of death due to any cause. |
From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
|
|
Objective Response Rate (ORR)
Tidsramme: From randomisation up until progression (anticipated to be up to 33 months).
|
ORR is defined as the proportion of participants who have a CR or PR, as determined by the BICR/investigator assessment, per RECIST 1.1. |
From randomisation up until progression (anticipated to be up to 33 months).
|
|
Duration of Response (DoR)
Tidsramme: From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
|
DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause. |
From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
|
|
Progression-Free Survival (PFS) by Investigator assessment
Tidsramme: From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause. |
From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
|
|
Clinical Benefit Rate (CBR) at 24 weeks
Tidsramme: From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
|
CBR at 24 weeks is defined as the percentage of participants who have a CR or PR or who have SD, per RECIST 1.1, as assessed by BICR/per investigator assessment and derived from the raw tumour data for at least 23 weeks after randomisation. |
From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
|
|
Time to deterioration (TTD) in breast and arm symptoms in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tidsramme: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in breast symptoms and arm symptoms as measured by the arm symptoms scale from EORTC IL116 TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in pain in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tidsramme: Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in pain as measured by the EORTC IL199. |
Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in physical functioning in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tidsramme: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in GHS/QoL in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tidsramme: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to First Subsequent Therapy (TFST)
Tidsramme: From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
|
TFST is defined as the time from randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause. |
From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
|
|
Time to Second Subsequent Therapy (TSST)
Tidsramme: From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
|
TSST is defined as the time from randomisation until the start date of the second subsequent anticancer therapy after discontinuation of first subsequent treatment, or death due to any cause. |
From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
|
|
Progression Free Survival 2 (PFS2)
Tidsramme: From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
|
PFS2 will be defined as the time from the randomisation to the earliest progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice based on radiological or clinical progression. |
From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
|
|
Pharmacokinetics of Dato-DXd in combination with durvalumab
Tidsramme: From first dose to end of treatment (anticipated to be up to 33 months).
|
Concentration of Dato-DXd, total anti-TROP2 antibody, and DXd (payload) in plasma. |
From first dose to end of treatment (anticipated to be up to 33 months).
|
|
Immunogenicity of Dato-DXd in combination with durvalumab
Tidsramme: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
Presence of antidrug antibodies for Dato-DXd (confirmatory results: positive or negative, titres). |
From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
|
Safety and tolerability of Dato-DXd + durvalumab as compared with ICC + pembrolizumab
Tidsramme: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
Safety and tolerability will be evaluated in the safety population in terms of AEs. |
From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Neoplasmer efter sted
- Neoplasmer
- Neoplastiske processer
- Hudsygdomme
- Brystsygdomme
- Patologiske tilstande, tegn og symptomer
- Hud- og bindevævssygdomme
- Brystneoplasmer
- Neoplasma Metastase
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Kulbrinter
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Koordinationskomplekser
- Taxoider
- Cyclodecanes
- Diterpenes
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Gemcitabin
- Carboplatin
- Paclitaxel
- pembrolizumab
- Durvalumab
- 130-nm albuminbundet paclitaxel
Andre undersøgelses-id-numre
- D7630C00001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delingsadgangskriterier
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .